Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies
Brief Summary: This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.


Options:
A: Arm Label: Sequence 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CP-690,550 or Placebo | Arm Label: Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550 or Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 2
B: Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
D: Arm Label: ADA+MTX/PBO+MTX (Arm 1); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Arm Label: ADA+MTX/ADA+MTX (Arm2); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: ADA+MTX/OL ADA+MTX (Arm 3); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: PBO+MTX/PBO+MTX (Arm 4); Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Biological: placebo | Arm Label: PBO+MTX/OL ADA+MTX (Arm 5); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5) | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4) | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4)

Answer: B